Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: The INNOVO multicentre randomised controlled trial (ISRCTN 17821339)

Pediatrics

Volumn 115, Issue 4, 2005, Pages 926-936

  Field, D ^a   Elbourne, D ^b   Truesdale, A ^b   Grieve, R ^b   Hardy, P ^b   Fenton, A C ^c   Subhedar, N ^d   Ahluwalia, J ^e   Halliday, H L ^f   Stocks, J ^g   Tomlin, K ^b   Normand, C ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^e Rosie Maternity Hospital   (United Kingdom)

^f ROYAL MATERNITY HOSPITAL   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Neonatal intensive care; Nitric oxide; Preterm infants; Ventilation

Indexed keywords

NITRIC OXIDE;

ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; FEMALE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OXYGEN SUPPLY; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; UNITED KINGDOM; DEVELOPMENTAL DISORDER; ECONOMICS; HANDICAPPED CHILD; HEALTH CARE COST; HEALTH CARE PLANNING; INHALATIONAL DRUG ADMINISTRATION; LENGTH OF STAY; LUNG DISEASE; MULTIMODALITY CANCER THERAPY; NEWBORN; TREATMENT FAILURE; UTILIZATION REVIEW;

ADMINISTRATION, INHALATION; COMBINED MODALITY THERAPY; DEVELOPMENTAL DISABILITIES; DISABLED CHILDREN; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LENGTH OF STAY; LUNG DISEASES; MALE; NITRIC OXIDE; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; TREATMENT FAILURE;

EID: 22444433630     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-1209     Document Type: Article

References (22)

1. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. In: The Cochrane Library. Issue 4. Chichester, United Kingdom: John Wiley & Sons; 2003
2. Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet. 1999;354:1061-1065
3. Franco-Belgium collaborative NO trial group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet. 1999;354:1066-1071
4. Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed. 1997;77:F185-F190
5. Schreiber MD, Gin-Mestan K, Marks J, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 2003;349:2099-2107
6. Pan H, Goldstein H. Multi-level models for longitudinal growth norms. Stat Med. 1997;16:2665-2678
7. Department of Health. Reference Costs 2002 - National Schedule of Reference Costs. Leeds, United Kingdom: Department of Health; 2002
8. Netten A, Curtis L. Unit Costs of Health and Social Care 2002. Canterbury, United Kingdom: Personal Social Services Research Unit, University of Kent; 2002
9. SAS System for Windows [computer program]. Version 8.02. Cary, NC: SAS Institute; 1999
10. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. 1971;44:793-797
11. Organisation for Economic Co-operation and Development. Main Economic Indicators. Paris, France: Organisation for Economic Co-operation and Development; 2004
12. Thompson SG, Barber JA. How should cost data in pragmatic trials be analysed? BMJ. 2000;320:1197-2000
13. Normand CEM, Field D, Elbourne D, Truesdale A. Nitric oxide is not licensed for preterm neonates. BMJ. 2002;325:1244
14. Pierce CM, Peters MJ, Coghen G, Goldman AP, Petros AJ. Cost of nitric oxide is exorbitant. BMJ. 2002;325:336
15. Snowdon C, Elbourne DR, Garcia J. Perinatal pathology in the context of a clinical trial: attitudes of neonatologists and pathologists. Arch Dis Child Fetal Neonatal Ed. 2004;89:F204-F207
16. Kuint J, Reichman B, Neumann L, Shinwell ES. Prognostic value of the immediate response to surfactant. Arch Dis Child Fetal Neonatal Ed. 1994;71:F170-F173
17. Hamvas A, Devine T, Cole FS. Surfactant therapy failure identifies infants at risk for pulmonary mortality. Am J Dis Child. 1993;147:665-681
18. Ballard RA, Ballard PL, Cnaan A, et al. Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. North American Thyrotropin-Releasing Hormone Study Group. N Engl J Med. 1998;338:493-498
19. Ventriculomegaly Trial Group. Randomised trial of early tapping in neonatal posthaemorrhagic ventricular dilatation: results at 30 months. Arch Dis Child Fetal Neonatal Ed. 1994;70:F129-F136
20. International PHVD Drug Trial Group. International randomised controlled trial of acetazolamide and furosemide in posthaemorrhagic ventricular dilatation in infancy. Lancet. 1998;352:433-440
21. Martin RJ. Nitric oxide for preemies - not so fast. N Engl J Med. 2003;349:2157-2159
22. Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurological and developmental disability after extremely preterm birth. EPICure Study Group. N Engl J Med. 2000;343:378-384